This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Alternative Dosing Strategy for Anti-HIV Drugs

This study has been completed.
Information provided by:
National Institute of Allergy and Infectious Diseases (NIAID) Identifier:
First received: April 23, 2003
Last updated: September 16, 2008
Last verified: July 2007

Anti-HIV drugs are usually given to patients at fixed, standardized doses. This study will investigate alternative ways of dosing anti-HIV drugs to improve viral control.

Study hypothesis: The optimal dosage regimen required to obtain the maximum benefit from antiretroviral therapy is achieved with strategies that control for pharmacokinetic and pharmacodynamic variability among patients.

Condition Intervention Phase
HIV Infections Behavioral: Concentration-controlled therapy Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Concentration-Controlled Antiretroviral Therapy in Persons Experiencing Persistent Viremia

Resource links provided by NLM:

Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Primary Outcome Measures:
  • Ability of the concentration-controlled strategies to achieve and maintain target concentrations
  • safety and tolerability of pharmacologic intensification
  • ability of pharmacologic intensification to achieve and maintain a sustained suppression in plasma HIV RNA

Secondary Outcome Measures:
  • Cross clade neutralizing antibody
  • cellular immunity

Estimated Enrollment: 66
Study Start Date: January 2003
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Detailed Description:

While optimism for the benefits of antiretroviral therapy remain justified, the response to therapy varies widely. This variability arises because of differences among patients in virologic, immunologic, behavioral, and pharmacologic factors, all of which impact therapeutic success.

Antiretroviral agents are presently administered to adults in standard fixed doses. However, the same dose does not produce the same systemic and intracellular concentrations in all patients. Recent research has shown that adjusting the doses of antiretroviral agents to achieve target concentrations in plasma is associated with an improved anti-HIV response compared with standard dose therapy. This study will extend the paradigm of concentration-controlled therapy to develop intensified pharmacologic regimens for patients experiencing persistent viremia while receiving antiretroviral therapy.

Two approaches will be investigated: 1) a regimen that targets concentrations of each antiretroviral drug between the 50th and 75th percentile of expected concentrations in adults; and 2) a novel regimen in which the target concentrations are based upon a desired ratio between phenotypic drug susceptibility (IC90) and the concentrations of pharmacologically active moieties, specifically intracellular nucleoside triphosphates and unbound protease and nonnucleoside inhibitors.

Participants will be randomized to either one of the investigational approaches (Cohort II) or to a control group receiving standard dose therapy (Cohort I). There are two study visits in the first month; after the first month, study visits are scheduled monthly for five additional months. Study visits include laboratory tests of virologic and immunologic parameters, pharmacokinetic sampling, and adherence counseling and monitoring.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria for Cohort I:

  • HIV infected
  • Receiving therapy with 3 or more antiretroviral medications and and willing to continue this regimen
  • Achieved a greater than 1 log10 reduction in plasma HIV-RNA from baseline within 8 weeks after the start of current therapy
  • Current plasma HIV-RNA levels greater than 500 copies/mL and less than 10,000 copies/mL

Inclusion Criteria for Cohort Cohort II:

  • HIV infected
  • Receiving antiretroviral therapy and have been determined to have had virologic failure
  • Will or have been changed to a new antiretroviral regimen (addition of greater than one new antiretroviral agent), but have not received this new regimen for more than 4 weeks as of study entry
  • HIV RNA of 2500 copies/mL or greater at screening

Exclusion Criteria:

  • Concurrent investigational antiretroviral agent
  • Malignancy, including Kaposi's sarcoma, requiring systemic chemotherapy
  • Active opportunistic infection requiring therapy within 14 days prior to study entry
  • Drug-resistant mutations that necessitate a change in antiretroviral regimen
  • Active drug or alcohol use or dependence
  • Certain laboratory abnormalities
  • Pregnant or breastfeeding
  • Known nonadherence with medications and scheduled clinic visits
  • Any medical condition that, in the opinion of the investigators, would preclude successful completion of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00059384

United States, Colorado
University of Colorado Health Sciences Center
Denver, Colorado, United States, 80262
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator: Courtney V. Fletcher, PharmD University of Colorado, Denver
  More Information Identifier: NCT00059384     History of Changes
Other Study ID Numbers: 2R01AI033835-08A1 ( U.S. NIH Grant/Contract )
3M01RR000400-34S1 ( U.S. NIH Grant/Contract )
Study First Received: April 23, 2003
Last Updated: September 16, 2008

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Treatment experienced
Therapeutic Drug Monitoring

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases processed this record on September 21, 2017